BCAB Stock Analysis: Buy, Sell, or Hold?
BCAB - BioAtla, Inc. Common Stock
$5.65
5.52 (4232.82%)
▲
5d:
+3587.99%
30d:
+3265.1%
90d:
+957.66%
WAIT
LOW Confidence
Analysis Updated: Apr 6, 2026 12:00 AM ET
Earnings: May 05, 2026
28d
Get Alerted When BCAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: BCAB is 2725.0% above fair value ($0.20). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: BCAB is 2725.0% above fair value ($0.20). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: BCAB is currently trading at $5.65, which is considered oversold relative to its 30-day fair value range of $0.15 to $0.20.
Technical Outlook: Technically, BCAB is in a downtrend. Immediate support is located at $0.12, while resistance sits at $6.52. The stock is showing strong short-term momentum, up 4232.8% recently.
Market Sentiment: BCAB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+7568.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCAB is in a downtrend. Immediate support is located at $0.12, while resistance sits at $6.52. The stock is showing strong short-term momentum, up 4232.8% recently.
Market Sentiment: BCAB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+7568.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.15 -
$0.20
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4232.8%)
- BULLISH: Trading 7568.7% below Wall St target ($10.00)
- WARNING: Recommendation downgraded due to 2725.0% overvaluation
Fair Price Analysis
30-Day Fair Range
$0.15 -
$0.20
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.12
Resistance Level
$6.52
Current Trend
Downtrend
Technical data as of
Apr 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.10
Wall Street Target
$10.00
(+7568.7%)
Revenue Growth (YoY)
31.6%
Share & Embed Analysis
Last updated: April 06, 2026 4:18 PM ET
Data refreshes hourly during market hours. Next update: 5:18 PM
Data refreshes hourly during market hours. Next update: 5:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 59 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 59 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 57 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 62 BUY |
